Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. It is used to treat certain types of cancer [1].
What type of cancer does Onivyde treat?
Onivyde is indicated for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy [1]. It is administered in combination with leucovorin and fluorouracil [1].
How does Onivyde work?
As a liposomal formulation, Onivyde encapsulates irinotecan within lipid spheres [1]. This delivery method is designed to alter the drug's pharmacokinetics and pharmacodynamics, potentially improving its delivery to tumors and reducing systemic toxicity compared to non-liposomal irinotecan [1]. Irinotecan itself functions by inhibiting topoisomerase I, an enzyme crucial for DNA replication and repair in cancer cells [1]. By blocking this enzyme, Onivyde leads to DNA damage and cell death in cancer cells [1].
When does Onivyde's patent protection expire?
Patent information for Onivyde can be complex due to its formulation and potential method-of-use patents. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceutical products.
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, nausea, vomiting, fatigue, abdominal pain, and decreased appetite [1]. Serious side effects can include severe diarrhea, neutropenia, and hypersensitivity reactions [1]. Patients are advised to discuss potential risks and side effects with their healthcare provider.